Pharvaris NV

PHVS · NASDAQ

$31.41+$0.73 (+2.38%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $30.68

About PHVS

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 129 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Employees: 129
Headquarters: Leiden, Zuid-Holland
Listed: Feb 5, 2021
Sector: Health Care
Industry: Pharmaceuticals
Website: pharvaris.com

Leadership

Pharvaris NV executives
Name	Title	Since	Age
Berndt Modig	—	—	64
Jochen Knolle	—	—	72
Hans Schikan	—	2019	65
Anne Lesage	—	—	61
David Nassif	—	—	69
Anna Nijdam	—	—	40
Morgan Conn	—	—	53
Peng Lu	—	—	44
Wim Souverijns	—	—	51
Elisabeth Bjork	—	—	62
Anne De Jonge Schuermans	—	—	50
Robert Glassman	—	—	61
David Meeker	—	—	68
Viviane Monges	—	—	60

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.